Search
Search
Close this search box.

Excise taxes are sucking craft cultivators dry: Tantalus CEO

Dan Sutton of BC-based Tantalus Labs is calling on the cannabis industry to rally together to demand that the heavy excise tax burden on small- and medium-sized cultivators be reduced. 

“This is untenable, and new operators who have mortgaged their lives on a chance in this new industry are waking up to a financial picture that structurally sucks them dry even while succeeding in market,” he wrote in an impassioned Twitter thread.



Price drop pressure

Excise taxes can be as high as 30% on top line revenues when prices are as low as they are, according to Sutton — higher than both alcohol and tobacco.

While the future of smaller cultivators is threatened, larger companies are an advantage when it comes to survival: “[They’re] happy to sell at a gross margin loss, with unit economics that would be laughable in any healthy ‘CPG’ model,” he tweeted.

American dreams

While selling at a loss is no long-term business model, many say larger LPs can stay in the game longer with the hope that profitability comes in the US if and when the country passes reform to allow them access to the market.

“Well-heeled pubcos are using Canada as a playground to fund US initiatives, while the government sucks out whatever is left,” wrote Stoic Advisory’s Aaron Salz. “Without significant structural change, it’s hard to see small and medium sized Canadian companies surviving in any meaningful way.”

Signs of solidarity

Sutton said he’s committed to push for lower taxes, and he hopes for support from colleagues and organizations representing the industry.

“You will see more from me and others on this front,” he concluded. “If you are the kind of person who cheers for local brands, quality products, and deep personal stories behind the companies you support, stand with us.”

⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?